Acarix ABACIXF 47 Beneish M-Score is -3.30 as of Jun. 24, 2026. GuruFocus rates ACIXF with a GF Score™ of 47/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 765 Medical Devices & Instruments companies, Acarix AB ranks better than 85.23% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -3.3 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Acarix AB's Beneish M-Score or its related term are showing as below:
ACIXF'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.65 Med: -2.46 Max: 106.68
Current: -3.3
During the past 12 years, the highest Beneish M-Score of Acarix AB was 106.68. The lowest was -3.65. And the median was -2.46.
Acarix AB Beneish M-Score Related Terms
Acarix AB Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Acarix AB's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACIXF vs ABT, SYK, MDT: Beneish M-Score Comparison
For the Medical Devices subindustry, Acarix AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Acarix AB's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Acarix AB for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.9261
+
0.528 * 1.035
+
0.404 * 1.0292
+
0.892 * 1.4098
+
0.115 * 0.9703
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.6172
+
4.679 * -0.163632
-
0.327 * 2.0167
=
-3.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(0.332 / (0.332 + 0.031))
/
(0.345 / (0.345 + 0.021))
=
0.914601
/
0.942623
=
0.9703
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-4.553 - 0
-
-3.789)
/
4.669
=
-0.163632
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Acarix AB has a M-score of -3.19 suggests that the company is unlikely to be a manipulator.
Acarix AB (ACIXF) has a Beneish M-Score of -3.30 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Acarix AB and its competitors. According to the industry distribution chart, Acarix AB ranks #113 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 14.8%.
Is Acarix AB's Beneish M-Score too high?
Acarix AB's current Beneish M-Score is -3.30. Based on the distribution chart, Acarix AB ranks #113 out of 765 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #113 out of 765 companies for Beneish M-Score. This places Acarix AB in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Acarix AB and its competitors. Acarix AB's current Beneish M-Score is -3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 45% above its estimated fair value. The current Beneish M-Score is -3.30. Acarix AB's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Beneish M-Score is -3.30 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 45% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
Beneish M-Score: -3.30
GF Value™: $0.02 vs. price of $0.03 (45% above fair value)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
47GF Score
Get the complete analysis for ACIXF
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
